Author:
Wang Zhen,Ye Jian,Hu Junjie,Zhang Nan,Yuan Yichu
Abstract
Abstract
Background
Small round cell tumor (SRCT) is a group of malignancy with similar optical microscopic morphology. Despite its low incidence, SRCT has a high malignant degree and poor prognosis. Besides, atypical clinical symptoms make it difficult in preoperative diagnosis.
Case report
A 67-year-old man was presented to the outpatient service with dysuria and weak urine stream lasting for 3 months. After oral treatment with tamsulosin and finasteride for 2 months, the symptoms worsen. Transurethral prostate holmium laser enucleation was operated and postoperative pathology result revealed small blue round cell malignant tumor. Further immunohistochemistry and fluorescence in situ hybridization examination indicated Ewing-like SRCT. So a Da Vinci Robotic prostatectomy was performed further and whole-genome sequencing was conducted. Several gene mutations including RAF1, ARID1A, SMARCA4, and BCL2L11 were found but no FDA-approved drug could treat specifically. Then the patient received Ewing-type therapeutic regimens treatment and has been followed up to date (over 24 months).
Conclusion
Because of its non-elevated serum PSA level, prostate SRCT is often ignored as a possibility of malignant tumor and regarded as benign prostatic hyperplasia (BPH). The possibility of prostate SRCT need to be considered if dysuria symptoms could not alleviate significantly after a period of oral treatment.
Funder
National Natural Science Foundation of China
Medical Science and Technology Project of Zhejiang Province
Publisher
Springer Science and Business Media LLC
Reference24 articles.
1. Antonescu C (2014) Round cell sarcomas beyond Ewing: emerging entities. Histopathology 64(1):26–37
2. Davis JM, Navolanic PM, Weinstein-Oppenheimer CR et al (2003) Raf-1 and Bcl-2 induce distinct and common pathways that contribute to breast cancer drug resistance. Clin Cancer Res off J Am Assoc Cancer Res 9(3):1161–1170
3. El-Ashry D, Miller DL, Kharbanda S, Lippman ME, Kern FG (1997) Constitutive Raf-1 kinase activity in breast cancer cells induces both estrogen-independent growth and apoptosis. Oncogene 15(4):423–435
4. Fillmore CM, Xu C, Desai PT et al (2015) EZH2 inhibition sensitizes BRG1 and EGFR mutant lung tumours to TopoII inhibitors. Nature 520(7546):239–242
5. Huang HN, Lin MC, Huang WC, Chiang YC, Kuo KT (2014) Loss of ARID1A expression and its relationship with PI3K-Akt pathway alterations and ZNF217 amplification in ovarian clear cell carcinoma. Modern Pathol off J U S Can Acad Pathol. 27(7):983–990